Co-Authors
This is a "connection" page, showing publications co-authored by Jaydutt Vadgama and Richard Pietras.
Connection Strength
1.028
-
Sterling C, M?rquez-Garb?n D, Vadgama JV, Pietras RJ. Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. Cancers (Basel). 2022 Oct 21; 14(20).
Score: 0.227
-
Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018 Sep 21; 9(74):33912-33930.
Score: 0.171
-
Hamilton N, Austin D, M?rquez-Garb?n D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
Score: 0.161
-
Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460.
Score: 0.154
-
Hamilton N, M?rquez-Garb?n D, Mah V, Fernando G, Elshimali Y, Garb?n H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-? and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703.
Score: 0.134
-
Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-? and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90.
Score: 0.132
-
Su F, Gm A, Palgunachari MN, White CR, Stessman H, Wu Y, Vadgama J, Pietras R, Nguyen D, Reddy ST, Farias-Eisner R. Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. J Cancer Res Ther Oncol. 2020; 8(1).
Score: 0.047